Mumbai, Nov. 4 -- The product has been deemed bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (NDA - 019443).

Glenmark plans to begin distribution in November 2025, further strengthening its injectables portfolio in the US market.

According to IQVIA sales data for the 12-month period ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) achieved annual sales of approximately $63.8 million.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, "We are pleased

to announce the expansion of our injectable portfolio to include t...